CHESTNUT HILL, Mass.--(BUSINESS WIRE)-- AuxoCell Laboratories, Inc., a leading stem cell therapeutic and regenerative medicine company, today announced an agreement with PerkinElmer, Inc. (NYSE: PKI), a global leader focused on the health and safety of people and the environment, to license its stem cell tissue service to ViaCord, PerkinElmer’s family cord blood banking business. This means families can bank newborn stem cells from an additional source – cord tissue.
“AuxoCell is pleased to partner with PerkinElmer’s ViaCord in offering umbilical cord tissue banking and expand our strategic partnerships to bring novel stem cell therapies from the bench to the bedside,” said Kyle Cetrulo, chief operating officer of AuxoCell Laboratories, Inc. “Partnering with ViaCord was an easy decision. They are the first family bank in the United States to freeze treatment-ready cord tissue stem cells upon arrival at the lab, which enables them to be ready for immediate use, if needed.”
Stem cell tissue is an abundant source of mesenchymal stem cells (MSCs), enabling families to secure newborn stem cells from an additional source. Currently, there is a significant amount of research underway to better understand the potential value of stem cells extracted from cord tissue. More than 50 studies using MSCs extracted from cord tissue have been published to underscore the importance to the scientific community.
“ViaCord is excited to offer another source of stem cells to our customers and believe we have found an excellent partner in AuxoCell. The agreement grants ViaCord’s customers exclusive access, in family banking, to expanding MSCs derived from cord tissue through AuxoCell’s elite patents,” said Morey Kraus, ViaCord’s chief scientific officer. “AuxoCell’s proprietary and validated manufacturing protocols will assist ViaCord in offering the very best in stem cell banking.”
Banking both cord blood and cord tissue provides a greater number and variety of stem cells, so patients may significantly increase their chances of success and benefit from the potential to treat additional diseases and disorders. Researchers in a preclinical study discovered that combining the stem cells from cord tissue with stem cells from cord blood results in improved engraftment – up to a six-fold increase over cord blood alone. As new scientific discoveries are made, cord tissue stem cells have been shown to offer potential treatment of additional disorders like Parkinson’s and sports injuries.
AuxoCell Laboratories, Inc. (AuxoCell) is a leading stem cell therapeutic and regenerative medicine company located in Massachusetts. AuxoCell's primary research focus is to develop the enormous therapeutic potential of the primitive stem cells found in the Wharton's Jelly of the human umbilical cord. With exclusive patent rights and proprietary processing protocols, AuxoCell is uniquely situated to offer the very best in cord tissue stem cell banking. Through strategic partnerships with both private and public cord blood banks, stem cell centers, and research laboratories around the world, AuxoCell strives every day to bring novel stem cell therapies from the bench to the bedside. Additional information is available through www.auxocell.com or at (617) 610-9000.
Auxocell Laboratories, Inc.
Kyle Cetrulo, 617-610-9000
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Stem Cells Health Biotechnology Genetics Oncology Baby/Maternity Research Consumer Family Science